Please Wait.....
Report
Clinical Trial Imaging Market by Software & Service (Operational Imaging, Trial Design), Modality (CT, MRI, X-Ray, PET, Ultrasound), Therapeutic Area (Infectious, Oncology, CNS, CVD), End User (Pharma, Biotech, CROs) - Global Forecast to 2029
Market Report I 2024-10-03 I 249 Pages I MarketsandMarkets
According to projections, the global clinical trial imaging market is expected to grow at a compound annual growth rate (CAGR) of 7.8%, from USD 1.42 billion in 2024 to USD 2.07 billion by 2029. Factors driving the market's growth include the biotechnology and pharmaceutical industries' expansion, the rise in R&D spending, and the number of Contract Research Organizations (CROs). However, the primary factors impeding the market's growth during the projection period are the high cost of clinical trials and the high implementation cost of imaging systems.
By service & software, the service sector had the fastest growth rate in the clinical trial imaging market throughout the projected period.
Based on type, services and software comprise the clinical trial imaging industry. In the clinical trial imaging market in 2023, the service sector had the fastest growth rate. The operational imaging services, reader analysis services, system & technical support services, and trial design consulting services are further subdivided under the services sector based on type. Growing R&D expenditures, an increase in clinical trials, and the need for novel illness treatments and diagnostics are the main factors contributing to this segment's growth.
Medical device manufacturers segment accounted for the highest CAGR.
The pharmaceutical and biotechnology firms, medical device manufacturers, contract research organizations, academic and government research institutes, and other end users are the segments of the clinical trial imaging market based on end user. The segment with the highest growth rate in 2023 was medical device manufacturers. This can be explained by the fact that the major growth drivers of the medical device manufacturers segment are the rising R&D expenditures and R&D activity by medical device manufacturers as well as the growing medical device market.
Asia Pacific: The fastest-growing region clinical trial imaging market.
The markets for clinical trial imaging across North America, Europe, Asia Pacific, Latin America, the Middle East and Africa and GCC countries comprise the global market. Over the course of the projection period, the Asia Pacific area is expected to record the greatest CAGR. The large number of SMEs, the presence of a large treatment-naive population for clinical trials, less-stringent regulations governing the use of animals in clinical research, the availability of local CROs with strong regulatory and linguistic understanding, the presence of highly qualified researchers, and the low cost of clinical trials are the major factors driving the R&D sector. These drivers driving the market's expansion are therefore due to the rise in R&D expenditures and the increasing trend of outsourcing pharmaceutical research to developing Asian countries.
The primary interviews conducted for this report can be categorized as follows:
By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
By Designation: C-level - 27%, D-level - 18%, and Others - 55%
By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America 6%, and the Middle East & Africa 4%
Prominent companies are ICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), Medpace Holdings, Inc. (US), IXICO plc. (UK), Resonance Health Ltd. (Australia), Radiant Sage LLC. (US), BioClinica Inc. (US), Intrinsic Imaging LLC. (US), Cardiovascular Imaging Technologies LLC. (US), Medical Metrics Inc. (US), Prism Clinical Imaging, Inc. (US), Boston Imaging Core Lab LLC. (US), anagram 4 clinical trials (Spain), Lyscaut Medical Imaging Company (Belgium), Calyx Group (UK), Bioseptive Inc. (Canada), ProScan Imaging LLC. (US), Micron Inc. (Japan), Imaging Endpoints LI, LLC (US), Perspectum Ltd. (UK), Pharmtrace klinische Entwicklung GmbH (Germany), WorldCare Clinical, LLC (US), Median Technologies (France) and Invicro. LLC. (US).
Research Coverage:
This research report categorizes the clinical trial imaging market by service & software, modality, therapeutic area, end user and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the clinical trial imaging market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the clinical trial imaging market. Competitive analysis of upcoming startups in the clinical trial imaging market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall clinical trial imaging market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the clinical trial imaging market.
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the clinical trial imaging market.
Market Development: Comprehensive information about lucrative markets the report analyses the clinical trial imaging market across varied regions.
Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the clinical trial imaging market.
Competitive Assessment: In-depth assessment of market ranking, growth strategies and service offerings of leading players like ICON plc. (Ireland), BioTelemetry Inc. (US), Biomedical Systems Corporation (US), and Medpace Holdings, Inc. (US), among others in the clinical clinical trial imaging market strategies.
1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 30
1.3 STUDY SCOPE 31
1.3.1 SEGMENTS CONSIDERED 31
1.3.2 INCLUSIONS AND EXCLUSIONS 32
1.3.3 YEARS CONSIDERED 32
1.3.4 CURRENCY CONSIDERED 32
1.4 STAKEHOLDERS 33
1.5 SUMMARY OF CHANGES 33
2 RESEARCH METHODOLOGY 34
2.1 RESEARCH DATA 34
2.2 RESEARCH APPROACH 34
2.2.1 SECONDARY DATA 35
2.2.1.1 Key data from secondary sources 35
2.2.1.2 Objectives of secondary research 35
2.2.2 PRIMARY DATA 36
2.2.2.1 Objectives of primary research 36
2.2.2.2 Key data from primary sources 37
2.2.2.3 Key industry insights 38
2.2.2.4 Breakdown of primaries 38
2.3 MARKET SIZE ESTIMATION 39
2.3.1 BOTTOM-UP APPROACH 39
2.3.1.1 Company revenue estimation approach 40
2.3.1.2 Company presentations and primary interviews 40
2.3.1.3 Growth forecasts 40
2.3.1.4 CAGR projections 41
2.3.2 TOP-DOWN APPROACH 41
2.4 DATA TRIANGULATION 42
2.5 STUDY ASSUMPTIONS 43
2.6 RESEARCH LIMITATIONS 43
2.7 RISK ASSESSMENT 44
3 EXECUTIVE SUMMARY 45
?
4 PREMIUM INSIGHTS 49
4.1 CLINICAL TRIAL IMAGING MARKET OVERVIEW 49
4.2 CLINICAL TRIAL IMAGING MARKET SHARE, BY SERVICE & SOFTWARE, 2024 VS. 2029 49
4.3 CLINICAL TRIAL IMAGING MARKET SHARE, BY MODALITY, 2024 VS. 2029 50
4.4 CLINICAL TRIAL IMAGING MARKET SHARE, BY THERAPEUTIC AREA, 2024 VS. 2029 50
4.5 CLINICAL TRIAL IMAGING MARKET SHARE, BY END USER, 2024 VS. 2029 51
4.6 CLINICAL TRIAL IMAGING MARKET: REGIONAL GROWTH OPPORTUNITIES 51
5 MARKET OVERVIEW 52
5.1 INTRODUCTION 52
5.2 MARKET DYNAMICS 52
5.2.1 DRIVERS 52
5.2.1.1 Increasing R&D spending in pharmaceutical and biotechnology companies 52
5.2.1.2 Rising number of clinical trials in medical research 53
5.2.1.3 Growth in pharmaceutical and biotechnology industries 54
5.2.1.4 Increasing number of contract research organizations 54
5.2.2 RESTRAINTS 54
5.2.2.1 High implementation cost of imaging systems 54
5.2.3 OPPORTUNITIES 55
5.2.3.1 Growth opportunities in emerging economies 55
5.2.3.2 Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals 55
5.2.4 CHALLENGES 55
5.2.4.1 High cost of clinical trials 55
5.3 PRICING ANALYSIS 56
5.3.1 INDICATIVE PRICING ANALYSIS FOR CLINICAL TRIAL IMAGING SERVICES & SOFTWARE, 20212023 56
5.4 PATENT ANALYSIS 57
5.4.1 LIST OF MAJOR PATENTS, 20222023 57
5.5 TRADE ANALYSIS 58
5.5.1 TRADE ANALYSIS FOR X-RAY APPARATUS (HS CODE 9022) 58
5.5.1.1 Import data for X-ray apparatus 58
5.5.1.2 Export data for X-ray apparatus 59
5.5.2 TRADE ANALYSIS FOR CT APPARATUS (HS CODE 902212) 59
5.5.2.1 Import data for CT apparatus 59
5.5.2.2 Export data for CT apparatus 60
5.6 VALUE CHAIN ANALYSIS 60
5.7 SUPPLY CHAIN ANALYSIS 61
5.8 ECOSYSTEM ANALYSIS 62
5.8.1 ROLE IN ECOSYSTEM 62
?
5.9 PORTERS FIVE FORCES ANALYSIS 63
5.9.1 THREAT OF NEW ENTRANTS 64
5.9.2 THREAT OF SUBSTITUTES 64
5.9.3 BARGAINING POWER OF BUYERS 64
5.9.4 BARGAINING POWER OF SUPPLIERS 64
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 65
5.10 KEY STAKEHOLDERS AND BUYING CRITERIA 65
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 65
5.10.2 KEY BUYING CRITERIA 66
5.11 REGULATORY ANALYSIS 67
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 67
5.12 KEY CONFERENCES AND EVENTS IN 20232024 71
5.13 TECHNOLOGY ANALYSIS 72
5.13.1 KEY TECHNOLOGIES 72
5.13.1.1 CT and MRI 72
5.13.2 COMPLEMENTARY TECHNOLOGIES 72
5.13.2.1 Ultrasound 72
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 73
5.15 CASE STUDY ANALYSIS 73
5.15.1 REVIEW OF CT FINDINGS AND HISTOPATHOLOGICAL CHARACTERISTICS OF PRIMARY LIVER CARCINOSARCOMA 73
5.16 IMPACT OF AI/GENERATIVE AI ON CLINICAL TRIAL IMAGING MARKET 74
6 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE 76
6.1 INTRODUCTION 77
6.2 SERVICES 77
6.2.1 OPERATIONAL IMAGING SERVICES 79
6.2.1.1 Rising number of CROs and growing pharmaceutical industry to drive market 79
6.2.2 READ ANALYSIS SERVICES 81
6.2.2.1 Increasing number of clinical trials and rising R&D spending to support market growth 81
6.2.3 SYSTEM AND TECHNICAL SUPPORT SERVICES 83
6.2.3.1 Need for continuous technical support to propel segment growth 83
6.2.4 TRIAL DESIGN AND CONSULTING SERVICES 85
6.2.4.1 High R&D spending and favorable government initiatives for clinical trials to fuel market growth 85
6.3 SOFTWARE 87
6.3.1 NEED FOR HIGHLY EFFICIENT AND COST-EFFECTIVE CLINICAL OPERATIONS SOFTWARE TO FAVOR MARKET GROWTH 87
?
7 CLINICAL TRIAL IMAGING MARKET, BY MODALITY 90
7.1 INTRODUCTION 91
7.2 COMPUTED TOMOGRAPHY 91
7.2.1 HIGHER CONTRAST IMAGE AND QUICKER TEST RESULTS TO AUGMENT SEGMENT GROWTH 91
7.3 MAGNETIC RESONANCE IMAGING 94
7.3.1 GREATER OBJECTIVITY, SENSITIVITY, AND REPRODUCIBILITY TO PROPEL MARKET GROWTH 94
7.4 ULTRASOUND 96
7.4.1 COST-EFFECTIVENESS AND EASE OF USE TO FUEL MARKET GROWTH 96
7.5 POSITRON EMISSION TOMOGRAPHY 99
7.5.1 ABILITY TO ASSESS PHARMACOKINETIC AND PHARMACODYNAMIC EVENTS IN HUMANS AND ANIMALS TO BOOST MARKET GROWTH 99
7.6 X-RAY 101
7.6.1 LOW SCANNING COST AND TECHNOLOGICAL ADVANCEMENTS TO FAVOR MARKET GROWTH 101
7.7 OTHER MODALITIES 103
8 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA 106
8.1 INTRODUCTION 107
8.2 ONCOLOGY 107
8.2.1 GROWING INCIDENCE OF CANCER AND INCREASING R&D INVESTMENTS BY PHARMA COMPANIES TO AID MARKET GROWTH 107
8.3 INFECTIOUS DISEASES 110
8.3.1 RISING DRUG DISCOVERY ACTIVITY AND GROWING DEMAND FOR THERAPEUTICS TO SPUR MARKET GROWTH 110
8.4 NEUROLOGY 112
8.4.1 HIGH RESEARCH INVESTMENTS FOR NEUROLOGIC DRUGS TO PROPEL MARKET GROWTH 112
8.5 CARDIOVASCULAR SYSTEM DISORDERS 114
8.5.1 HIGH MORTALITY RATE AND COMPLEX CLINICAL TRIAL PROCEDURES TO AUGMENT MARKET GROWTH 114
8.6 ENDOCRINOLOGY 116
8.6.1 RISING PREVALENCE OF DIABETES AND INCREASING RESEARCH FUNDING FOR METABOLIC DISORDERS TO DRIVE MARKET 116
8.7 IMMUNOLOGICAL DISORDERS 119
8.7.1 WIDE PREVALENCE OF ALLERGIES, ASTHMA, AND AUTOIMMUNE DISEASES TO SUPPORT MARKET GROWTH 119
8.8 OTHER THERAPEUTIC AREAS 121
?
9 CLINICAL TRIAL IMAGING MARKET, BY END USER 124
9.1 INTRODUCTION 125
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 125
9.2.1 HIGH R&D BUDGETS AND FAVORABLE GOVERNMENT INITIATIVES TO SUPPORT MARKET GROWTH 125
9.3 MEDICAL DEVICE MANUFACTURERS 129
9.3.1 HIGH SPENDING ON R&D AND CLINICAL TRIALS TO SUPPORT MARKET GROWTH 129
9.4 CONTRACT RESEARCH ORGANIZATIONS 131
9.4.1 INCREASING TREND OF OUTSOURCING AND GROWING PATIENT POPULATION IN EMERGING ECONOMIES TO AID MARKET GROWTH 131
9.5 ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES 134
9.5.1 RISING RESEARCH FUNDING AND INCREASING GOVERNMENT SUPPORT FOR CLINICAL TRIALS TO BOOST MARKET GROWTH 134
9.6 OTHER END USERS 136
10 CLINICAL TRIAL IMAGING MARKET, BY REGION 139
10.1 INTRODUCTION 140
10.2 NORTH AMERICA 140
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 143
10.2.2 US 144
10.2.2.1 US to dominate North American clinical trial imaging market during study period 144
10.2.3 CANADA 147
10.2.3.1 Increase in per capita healthcare spending to augment market growth 147
10.3 EUROPE 149
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 152
10.3.2 GERMANY 153
10.3.2.1 Strong medical technology infrastructure and increased funding for biomedical research to augment market growth 153
10.3.3 UK 155
10.3.3.1 Increased R&D investments and high per capita healthcare expenditure to augment market growth 155
10.3.4 FRANCE 157
10.3.4.1 Developed generics market and favorable government healthcare policies to support market growth 157
10.3.5 ITALY 159
10.3.5.1 Increasing number of drug approvals and rising investments in clinical trials to drive market 159
10.3.6 SPAIN 161
10.3.6.1 Increased biologics production and improved healthcare infrastructure to aid market growth 161
10.3.7 REST OF EUROPE 164
?
10.4 ASIA PACIFIC 167
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 170
10.4.2 CHINA 171
10.4.2.1 Favorable government regulations and presence of large target patient population to boost market growth 171
10.4.3 JAPAN 173
10.4.3.1 Increasing geriatric population and rising healthcare expenditure to favor market growth 173
10.4.4 INDIA 176
10.4.4.1 Increased government focus on developing advanced healthcare infrastructure to augment market growth 176
10.4.5 REST OF ASIA PACIFIC 178
10.5 LATIN AMERICA 181
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 183
10.5.2 BRAZIL 184
10.5.2.1 Increasing investments in biopharmaceutical research to propel market growth 184
10.5.3 MEXICO 186
10.5.3.1 Developed pharmaceutical and biotechnology industry and high demand for personalized medicines to aid market growth 186
10.5.4 REST OF LATIN AMERICA 188
10.6 MIDDLE EAST & AFRICA 191
10.6.1 INCREASED FUNDING AND COLLABORATIONS IN RESEARCH SECTOR TO DRIVE MARKET 191
10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 193
10.7 GCC COUNTRIES 194
10.7.1 INCREASING RESEARCH ACTIVITIES AND GROWING BIOTECHNOLOGY INDUSTRY TO SPUR MARKET GROWTH 194
10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 197
11 COMPETITIVE LANDSCAPE 198
11.1 INTRODUCTION 198
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN 198
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CLINICAL TRIAL IMAGING MARKET 198
11.3 REVENUE ANALYSIS, 20212023 199
11.4 MARKET SHARE ANALYSIS, 2023 200
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (2023) 202
11.5.1 STARS 202
11.5.2 EMERGING LEADERS 202
11.5.3 PERVASIVE PLAYERS 202
11.5.4 PARTICIPANTS 202
?
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 203
11.5.5.1 Company footprint 203
11.5.5.2 Service & software footprint 204
11.5.5.3 Therapeutic area footprint 204
11.5.5.4 Region footprint 204
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 205
11.6.1 PROGRESSIVE COMPANIES 205
11.6.2 RESPONSIVE COMPANIES 205
11.6.3 DYNAMIC COMPANIES 205
11.6.4 STARTING BLOCKS 205
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 206
11.7 COMPANY VALUATION AND FINANCIAL METRICS 207
11.8 COMPETITIVE SCENARIO 208
11.8.1 SERVICE AND SOLUTION LAUNCHES AND REGULATORY APPROVALS 208
11.8.2 DEALS 209
12 COMPANY PROFILES 210
12.1 KEY PLAYERS 210
12.1.1 ICON PLC 210
12.1.1.1 Business overview 210
12.1.1.2 Services/Solutions offered 211
12.1.1.3 Recent developments 211
12.1.1.3.1 Solution launches 211
12.1.1.3.2 Deals 212
12.1.1.4 MnM view 212
12.1.1.4.1 Key strengths 212
12.1.1.4.2 Strategic choices 212
12.1.1.4.3 Weaknesses and competitive threats 213
12.1.2 MEDPACE 214
12.1.2.1 Business overview 214
12.1.2.2 Services/Solutions offered 215
12.1.2.3 MnM view 215
12.1.2.3.1 Key strengths 215
12.1.2.3.2 Strategic choices 215
12.1.2.3.3 Weaknesses and competitive threats 215
?
12.1.3 CLARIO 216
12.1.3.1 Business overview 216
12.1.3.2 Services/Solutions offered 216
12.1.3.3 Recent developments 217
12.1.3.3.1 Solution launches 217
12.1.3.3.2 Deals 217
12.1.3.4 MnM view 218
12.1.3.4.1 Key strengths 218
12.1.3.4.2 Strategic choices 218
12.1.3.4.3 Weaknesses and competitive threats 218
12.1.4 IXICO PLC 219
12.1.4.1 Business overview 219
12.1.4.2 Services/Solutions offered 220
12.1.4.3 Recent developments 221
12.1.4.3.1 Deals 221
12.1.4.3.2 Other developments 221
12.1.5 RESONANCE HEALTH LTD. 222
12.1.5.1 Business overview 222
12.1.5.2 Services/Solutions offered 223
12.1.5.3 Recent developments 224
12.1.5.3.1 Service launches and regulatory approvals 224
12.1.5.3.2 Deals 224
12.1.6 RADIANT SAGE 225
12.1.6.1 Business overview 225
12.1.6.2 Services/Solutions offered 225
12.1.7 WCG CLINICAL 226
12.1.7.1 Business overview 226
12.1.7.2 Services/Solutions offered 226
12.1.7.3 Recent developments 226
12.1.7.3.1 Deals 226
12.1.8 CARDIOVASCULAR IMAGING TECHNOLOGIES 227
12.1.8.1 Business overview 227
12.1.8.2 Services/Solutions offered 227
12.2 OTHER PLAYERS 228
12.2.1 MEDICAL METRICS, INC. 228
12.2.2 PRISM CLINICAL IMAGING 229
12.2.3 BOSTON IMAGING CORE LAB 230
12.2.4 ANAGRAM 4 CLINICAL TRIALS 231
12.2.5 VOIANT 231
?
12.2.6 CALYX 232
12.2.7 BIOSPECTIVE INC. 233
12.2.8 PROSCAN IMAGING 234
12.2.9 MICRON, INC. 235
12.2.10 IMAGING ENDPOINTS 236
12.2.11 PERSPECTUM 237
12.2.12 PHARMTRACE 237
12.2.13 NAVITAS LIFE SCIENCES 238
12.2.14 MEDIAN TECHNOLOGIES 238
12.2.15 INVICRO, LLC 239
12.2.16 IMAGE CORE LAB 239
12.2.17 IMAGE ANALYSIS GROUP (IAG) 240
13 APPENDIX 241
13.1 DISCUSSION GUIDE 241
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL 245
13.3 CUSTOMIZATION OPTIONS 247
13.4 RELATED REPORTS 247
13.5 AUTHOR DETAILS 248
TABLE 1 CLINICAL TRIAL IMAGING MARKET: INCLUSIONS AND EXCLUSIONS 32
TABLE 2 CLINICAL TRIAL IMAGING MARKET: KEY DATA FROM PRIMARY SOURCES 37
TABLE 3 CLINICAL TRIAL IMAGING MARKET: RISK ASSESSMENT ANALYSIS 44
TABLE 4 INDICATIVE SELLING PRICE TREND FOR CLINICAL TRIAL IMAGING SERVICES & SOFTWARE, 20212023 56
TABLE 5 CLINICAL TRIAL IMAGING MARKET: LIST OF KEY PATENTS,
JANUARY 2022DECEMBER 2023 57
TABLE 6 IMPORT DATA FOR X-RAY APPARATUS (HS CODE 9022), BY COUNTRY,
20182022 (USD MILLION) 58
TABLE 7 EXPORT DATA FOR X-RAY APPARATUS (HS CODE 9022), BY COUNTRY,
20182022 (USD MILLION) 59
TABLE 8 IMPORT DATA FOR CT APPARATUS (HS CODE 902212), BY COUNTRY,
20182022 (USD MILLION) 59
TABLE 9 EXPORT DATA FOR CT APPARATUS (HS CODE 902212), BY COUNTRY,
20182022 (USD MILLION) 60
TABLE 10 CLINICAL TRIAL IMAGING MARKET: ROLE IN ECOSYSTEM 62
TABLE 11 CLINICAL TRIAL IMAGING MARKET: IMPACT OF PORTERS FIVE FORCES 64
TABLE 12 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 66
TABLE 13 KEY BUYING CRITERIA FOR MAJOR END USERS 66
TABLE 14 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 67
TABLE 15 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 68
TABLE 16 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 69
TABLE 17 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 70
TABLE 18 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 70
TABLE 19 CLINICAL TRIAL IMAGING MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, JANUARY 2023DECEMBER 2024 71
TABLE 20 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
20222029 (USD MILLION) 77
TABLE 21 CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
20222029 (USD MILLION) 77
TABLE 22 CLINICAL TRIAL IMAGING SERVICES MARKET, BY REGION,
20222029 (USD MILLION) 78
TABLE 23 NORTH AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY COUNTRY, 20222029 (USD MILLION) 78
TABLE 24 EUROPE: CLINICAL TRIAL IMAGING SERVICES MARKET, BY COUNTRY,
20222029 (USD MILLION) 78
TABLE 25 ASIA PACIFIC: CLINICAL TRIAL IMAGING SERVICES MARKET, BY COUNTRY,
20222029 (USD MILLION) 79
TABLE 26 LATIN AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY COUNTRY, 20222029 (USD MILLION) 79
TABLE 27 OPERATIONAL IMAGING SERVICES MARKET, BY REGION,
20222029 (USD MILLION) 80
TABLE 28 NORTH AMERICA: OPERATIONAL IMAGING SERVICES MARKET, BY COUNTRY, 20222029 (USD MILLION) 80
TABLE 29 EUROPE: OPERATIONAL IMAGING SERVICES MARKET, BY COUNTRY,
20222029 (USD MILLION) 80
TABLE 30 ASIA PACIFIC: OPERATIONAL IMAGING SERVICES MARKET, BY COUNTRY,
20222029 (USD MILLION) 81
TABLE 31 LATIN AMERICA: OPERATIONAL IMAGING SERVICES MARKET, BY COUNTRY,
20222029 (USD MILLION) 81
TABLE 32 READ ANALYSIS SERVICES MARKET, BY REGION, 20222029 (USD MILLION) 82
TABLE 33 NORTH AMERICA: READ ANALYSIS SERVICES MARKET, BY COUNTRY,
20222029 (USD MILLION) 82
TABLE 34 EUROPE: READ ANALYSIS SERVICES MARKET, BY COUNTRY,
20222029 (USD MILLION) 82
TABLE 35 ASIA PACIFIC: READ ANALYSIS SERVICES MARKET, BY COUNTRY,
20222029 (USD MILLION) 83
TABLE 36 LATIN AMERICA: READ ANALYSIS SERVICES MARKET, BY COUNTRY,
20222029 (USD MILLION) 83
TABLE 37 SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET, BY REGION,
20222029 (USD MILLION) 84
TABLE 38 NORTH AMERICA: SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET,
BY COUNTRY, 20222029 (USD MILLION) 84
TABLE 39 EUROPE: SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET, BY COUNTRY, 20222029 (USD MILLION) 84
TABLE 40 ASIA PACIFIC: SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET,
BY COUNTRY, 20222029 (USD MILLION) 85
TABLE 41 LATIN AMERICA: SYSTEM AND TECHNICAL SUPPORT SERVICES MARKET,
BY COUNTRY, 20222029 (USD MILLION) 85
TABLE 42 TRIAL DESIGN AND CONSULTING SERVICES MARKET, BY REGION,
20222029 (USD MILLION) 86
TABLE 43 NORTH AMERICA: TRIAL DESIGN AND CONSULTING SERVICES MARKET,
BY COUNTRY, 20222029 (USD MILLION) 86
TABLE 44 EUROPE: TRIAL DESIGN AND CONSULTING SERVICES MARKET, BY COUNTRY, 20222029 (USD MILLION) 86
TABLE 45 ASIA PACIFIC: TRIAL DESIGN AND CONSULTING SERVICES MARKET, BY COUNTRY, 20222029 (USD MILLION) 87
TABLE 46 LATIN AMERICA: TRIAL DESIGN AND CONSULTING SERVICES MARKET,
BY COUNTRY, 20222029 (USD MILLION) 87
TABLE 47 CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY REGION,
20222029 (USD MILLION) 88
TABLE 48 NORTH AMERICA: CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY COUNTRY, 20222029 (USD MILLION) 88
TABLE 49 EUROPE: CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY COUNTRY,
20222029 (USD MILLION) 88
TABLE 50 ASIA PACIFIC: CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY COUNTRY,
20222029 (USD MILLION) 89
TABLE 51 LATIN AMERICA: CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY COUNTRY, 20222029 (USD MILLION) 89
TABLE 52 CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 20222029 (USD MILLION) 91
TABLE 53 CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY, BY REGION, 20222029 (USD MILLION) 92
TABLE 54 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY, BY COUNTRY, 20222029 (USD MILLION) 92
TABLE 55 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY,
BY COUNTRY, 20222029 (USD MILLION) 93
TABLE 56 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY, BY COUNTRY, 20222029 (USD MILLION) 93
TABLE 57 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR COMPUTED TOMOGRAPHY, BY COUNTRY, 20222029 (USD MILLION) 93
TABLE 58 CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING,
BY REGION, 20222029 (USD MILLION) 94
TABLE 59 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING, BY COUNTRY, 20222029 (USD MILLION) 95
TABLE 60 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING, BY COUNTRY, 20222029 (USD MILLION) 95
TABLE 61 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING, BY COUNTRY, 20222029 (USD MILLION) 95
TABLE 62 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR MAGNETIC RESONANCE IMAGING, BY COUNTRY, 20222029 (USD MILLION) 96
TABLE 63 CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY REGION,
20222029 (USD MILLION) 97
TABLE 64 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND,
BY COUNTRY, 20222029 (USD MILLION) 97
TABLE 65 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY COUNTRY, 20222029 (USD MILLION) 98
TABLE 66 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND, BY COUNTRY, 20222029 (USD MILLION) 98
TABLE 67 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ULTRASOUND,
BY COUNTRY, 20222029 (USD MILLION) 98
TABLE 68 CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY,
BY REGION, 20222029 (USD MILLION) 99
TABLE 69 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 20222029 (USD MILLION) 100
TABLE 70 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 20222029 (USD MILLION) 100
TABLE 71 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 20222029 (USD MILLION) 100
TABLE 72 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 20222029 (USD MILLION) 101
TABLE 73 CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY REGION,
20222029 (USD MILLION) 102
TABLE 74 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY COUNTRY, 20222029 (USD MILLION) 102
TABLE 75 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY COUNTRY,
20222029 (USD MILLION) 102
TABLE 76 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY COUNTRY,
20222029 (USD MILLION) 103
TABLE 77 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR X-RAY, BY COUNTRY, 20222029 (USD MILLION) 103
TABLE 78 CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES, BY REGION,
20222029 (USD MILLION) 104
TABLE 79 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES,
BY COUNTRY, 20222029 (USD MILLION) 104
TABLE 80 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES,
BY COUNTRY, 20222029 (USD MILLION) 105
TABLE 81 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES,
BY COUNTRY, 20222029 (USD MILLION) 105
TABLE 82 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER MODALITIES,
BY COUNTRY, 20222029 (USD MILLION) 105
TABLE 83 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
20222029 (USD MILLION) 107
TABLE 84 CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY REGION,
20222029 (USD MILLION) 108
TABLE 85 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY,
BY COUNTRY, 20222029 (USD MILLION) 108
TABLE 86 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY COUNTRY,
20222029 (USD MILLION) 109
TABLE 87 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY COUNTRY, 20222029 (USD MILLION) 109
TABLE 88 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ONCOLOGY, BY COUNTRY, 20222029 (USD MILLION) 109
TABLE 89 CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES, BY REGION, 20222029 (USD MILLION) 110
TABLE 90 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES BY COUNTRY, 20222029 (USD MILLION) 110
TABLE 91 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 20222029 (USD MILLION) 111
TABLE 92 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES
BY COUNTRY, 20222029 (USD MILLION) 111
TABLE 93 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR INFECTIOUS DISEASES
BY COUNTRY, 20222029 (USD MILLION) 111
TABLE 94 CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY REGION,
20222029 (USD MILLION) 112
TABLE 95 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY,
BY COUNTRY, 20222029 (USD MILLION) 113
TABLE 96 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY COUNTRY, 20222029 (USD MILLION) 113
TABLE 97 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY, BY COUNTRY, 20222029 (USD MILLION) 113
TABLE 98 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR NEUROLOGY,
BY COUNTRY, 20222029 (USD MILLION) 114
TABLE 99 CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 20222029 (USD MILLION) 114
TABLE 100 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 20222029 (USD MILLION) 115
TABLE 101 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 20222029 (USD MILLION) 115
TABLE 102 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 20222029 (USD MILLION) 115
TABLE 103 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 20222029 (USD MILLION) 116
TABLE 104 CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY, BY REGION,
20222029 (USD MILLION) 117
TABLE 105 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY,
BY COUNTRY, 20222029 (USD MILLION) 117
TABLE 106 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY, BY COUNTRY, 20222029 (USD MILLION) 118
TABLE 107 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY,
BY COUNTRY, 20222029 (USD MILLION) 118
TABLE 108 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ENDOCRINOLOGY,
BY COUNTRY, 20222029 (USD MILLION) 118
TABLE 109 CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 20222029 (USD MILLION) 119
TABLE 110 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 20222029 (USD MILLION) 120
TABLE 111 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 20222029 (USD MILLION) 120
TABLE 112 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 20222029 (USD MILLION) 120
TABLE 113 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 20222029 (USD MILLION) 121
TABLE 114 CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 20222029 (USD MILLION) 122
TABLE 115 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 20222029 (USD MILLION) 122
TABLE 116 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS,
BY COUNTRY, 20222029 (USD MILLION) 123
TABLE 117 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 20222029 (USD MILLION) 123
TABLE 118 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 20222029 (USD MILLION) 123
TABLE 119 CLINICAL TRIAL IMAGING MARKET, BY END USER, 20222029 (USD MILLION) 125
TABLE 120 CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 20222029 (USD MILLION) 127
TABLE 121 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 20222029 (USD MILLION) 127
TABLE 122 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 20222029 (USD MILLION) 128
TABLE 123 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 20222029 (USD MILLION) 128
TABLE 124 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 20222029 (USD MILLION) 128
TABLE 125 CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS,
BY REGION, 20222029 (USD MILLION) 129
TABLE 126 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 20222029 (USD MILLION) 130
TABLE 127 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS BY COUNTRY, 20222029 (USD MILLION) 130
TABLE 128 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 20222029 (USD MILLION) 130
TABLE 129 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 20222029 (USD MILLION) 131
TABLE 130 CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 20222029 (USD MILLION) 132
TABLE 131 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 20222029 (USD MILLION) 132
TABLE 132 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 20222029 (USD MILLION) 133
TABLE 133 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 20222029 (USD MILLION) 133
TABLE 134 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 20222029 (USD MILLION) 133
TABLE 135 CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY REGION, 20222029 (USD MILLION) 134
TABLE 136 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 20222029 (USD MILLION) 135
TABLE 137 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 20222029 (USD MILLION) 135
TABLE 138 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 20222029 (USD MILLION) 135
TABLE 139 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 20222029 (USD MILLION) 136
TABLE 140 CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS, BY REGION,
20222029 (USD MILLION) 136
TABLE 141 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS,
BY COUNTRY, 20222029 (USD MILLION) 137
TABLE 142 EUROPE: CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS, BY COUNTRY, 20222029 (USD MILLION) 137
TABLE 143 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS,
BY COUNTRY, 20222029 (USD MILLION) 137
TABLE 144 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET FOR OTHER END USERS,
BY COUNTRY, 20222029 (USD MILLION) 138
TABLE 145 CLINICAL TRIAL IMAGING MARKET, BY REGION, 20222029 (USD MILLION) 140
TABLE 146 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY,
20222029 (USD MILLION) 141
TABLE 147 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 20222029 (USD MILLION) 142
TABLE 148 NORTH AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
20222029 (USD MILLION) 142
TABLE 149 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
20222029 (USD MILLION) 142
TABLE 150 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 20222029 (USD MILLION) 143
TABLE 151 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
20222029 (USD MILLION) 143
TABLE 152 NORTH AMERICA: KEY MACROINDICATORS 144
TABLE 153 US: LIST OF PRODUCT APPROVALS BY KEY PLAYERS, 20202023 144
TABLE 154 US: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
20222029 (USD MILLION) 145
TABLE 155 US: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
20222029 (USD MILLION) 145
TABLE 156 US: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 20222029 (USD MILLION) 145
TABLE 157 US: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
20222029 (USD MILLION) 146
TABLE 158 US: CLINICAL TRIAL IMAGING MARKET, BY END USER, 20222029 (USD MILLION) 146
TABLE 159 CANADA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
20222029 (USD MILLION) 147
TABLE 160 CANADA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
20222029 (USD MILLION) 147
TABLE 161 CANADA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
20222029 (USD MILLION) 148
TABLE 162 CANADA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
20222029 (USD MILLION) 148
TABLE 163 CANADA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
20222029 (USD MILLION) 149
TABLE 164 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY,
20222029 (USD MILLION) 150
TABLE 165 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
20222029 (USD MILLION) 150
TABLE 166 EUROPE: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
20222029 (USD MILLION) 150
TABLE 167 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
20222029 (USD MILLION) 151
TABLE 168 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
20222029 (USD MILLION) 151
TABLE 169 EUROPE: CLINICAL TRIAL IMAGING MARKET, BY END USER,
20222029 (USD MILLION) 152
TABLE 170 EUROPE: KEY MACROINDICATORS 152
TABLE 171 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
20222029 (USD MILLION) 153
TABLE 172 GERMANY: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
20222029 (USD MILLION) 153
TABLE 173 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
20222029 (USD MILLION) 154
TABLE 174 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
20222029 (USD MILLION) 154
TABLE 175 GERMANY: CLINICAL TRIAL IMAGING MARKET, BY END USER,
20222029 (USD MILLION) 155
TABLE 176 UK: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
20222029 (USD MILLION) 155
TABLE 177 UK: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
20222029 (USD MILLION) 156
TABLE 178 UK: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 20222029 (USD MILLION) 156
TABLE 179 UK: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
20222029 (USD MILLION) 157
TABLE 180 UK: CLINICAL TRIAL IMAGING MARKET, BY END USER, 20222029 (USD MILLION) 157
TABLE 181 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
20222029 (USD MILLION) 158
TABLE 182 FRANCE: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
20222029 (USD MILLION) 158
TABLE 183 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
20222029 (USD MILLION) 158
TABLE 184 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
20222029 (USD MILLION) 159
TABLE 185 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY END USER,
20222029 (USD MILLION) 159
TABLE 186 ITALY: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
20222029 (USD MILLION) 160
TABLE 187 ITALY: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
20222029 (USD MILLION) 160
TABLE 188 ITALY: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
20222029 (USD MILLION) 160
TABLE 189 ITALY: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
20222029 (USD MILLION) 161
TABLE 190 ITALY: CLINICAL TRIAL IMAGING MARKET, BY END USER,
20222029 (USD MILLION) 161
TABLE 191 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
20222029 (USD MILLION) 162
TABLE 192 SPAIN: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
20222029 (USD MILLION) 162
TABLE 193 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
20222029 (USD MILLION) 163
TABLE 194 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
20222029 (USD MILLION) 163
TABLE 195 SPAIN: CLINICAL TRIAL IMAGING MARKET, BY END USER,
20222029 (USD MILLION) 164
TABLE 196 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 20222029(USD MILLION) 164
TABLE 197 REST OF EUROPE: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
20222029 (USD MILLION) 165
TABLE 198 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
20222029 (USD MILLION) 165
TABLE 199 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 20222029 (USD MILLION) 166
TABLE 200 REST OF EUROPE: CLINICAL TRIAL IMAGING MARKET, BY END USER,
20222029 (USD MILLION) 166
TABLE 201 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY,
20222029 (USD MILLION) 168
TABLE 202 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 20222029 (USD MILLION) 168
TABLE 203 ASIA PACIFIC: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
20222029 (USD MILLION) 168
TABLE 204 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
20222029 (USD MILLION) 169
TABLE 205 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
20222029 (USD MILLION) 169
TABLE 206 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY END USER,
20222029 (USD MILLION) 170
TABLE 207 ASIA PACIFIC: KEY MACROINDICATORS 170
TABLE 208 CHINA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
20222029 (USD MILLION) 171
TABLE 209 CHINA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
20222029 (USD MILLION) 172
TABLE 210 CHINA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
20222029 (USD MILLION) 172
TABLE 211 CHINA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
20222029 (USD MILLION) 173
TABLE 212 CHINA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
20222029 (USD MILLION) 173
TABLE 213 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
20222029 (USD MILLION) 174
TABLE 214 JAPAN: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
20222029 (USD MILLION) 174
TABLE 215 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
20222029 (USD MILLION) 175
TABLE 216 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
20222029 (USD MILLION) 175
TABLE 217 JAPAN: CLINICAL TRIAL IMAGING MARKET, BY END USER,
20222029 (USD MILLION) 176
TABLE 218 INDIA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
20222029 (USD MILLION) 177
TABLE 219 INDIA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
20222029 (USD MILLION) 177
TABLE 220 INDIA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
20222029 (USD MILLION) 177
TABLE 221 INDIA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
20222029 (USD MILLION) 178
TABLE 222 INDIA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
20222029 (USD MILLION) 178
TABLE 223 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 20222029 (USD MILLION) 179
TABLE 224 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 20222029 (USD MILLION) 179
TABLE 225 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
20222029 (USD MILLION) 179
TABLE 226 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 20222029 (USD MILLION) 180
TABLE 227 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY END USER,
20222029 (USD MILLION) 180
TABLE 228 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY COUNTRY,
20222029 (USD MILLION) 181
TABLE 229 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 20222029 (USD MILLION) 181
TABLE 230 LATIN AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
20222029 (USD MILLION) 182
TABLE 231 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
20222029 (USD MILLION) 182
TABLE 232 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 20222029 (USD MILLION) 183
TABLE 233 LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
20222029 (USD MILLION) 183
TABLE 234 LATIN AMERICA: KEY MACROINDICATORS 184
TABLE 235 BRAZIL: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
20222029 (USD MILLION) 184
TABLE 236 BRAZIL: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
20222029 (USD MILLION) 185
TABLE 237 BRAZIL: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
20222029 (USD MILLION) 185
TABLE 238 BRAZIL: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
20222029 (USD MILLION) 186
TABLE 239 BRAZIL: CLINICAL TRIAL IMAGING MARKET, BY END USER,
20222029 (USD MILLION) 186
TABLE 240 MEXICO: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
20222029 (USD MILLION) 187
TABLE 241 MEXICO: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
20222029 (USD MILLION) 187
TABLE 242 MEXICO: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
20222029 (USD MILLION) 187
TABLE 243 MEXICO: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
20222029 (USD MILLION) 188
TABLE 244 MEXICO: CLINICAL TRIAL IMAGING MARKET, BY END USER,
20222029 (USD MILLION) 188
TABLE 245 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 20222029 (USD MILLION) 189
TABLE 246 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 20222029 (USD MILLION) 189
TABLE 247 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 20222029 (USD MILLION) 190
TABLE 248 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 20222029 (USD MILLION) 190
TABLE 249 REST OF LATIN AMERICA: CLINICAL TRIAL IMAGING MARKET, BY END USER, 20222029 (USD MILLION) 191
TABLE 250 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 20222029 (USD MILLION) 192
TABLE 251 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 20222029 (USD MILLION) 192
TABLE 252 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
20222029 (USD MILLION) 192
TABLE 253 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 20222029 (USD MILLION) 193
TABLE 254 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING MARKET, BY END USER,
20222029 (USD MILLION) 193
TABLE 255 MIDDLE EAST & AFRICA: KEY MACROINDICATORS 194
TABLE 256 GCC COUNTRIES: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 20222029 (USD MILLION) 194
TABLE 257 GCC COUNTRIES: CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE,
20222029 (USD MILLION) 195
TABLE 258 GCC COUNTRIES: CLINICAL TRIAL IMAGING MARKET, BY MODALITY,
20222029 (USD MILLION) 195
TABLE 259 GCC COUNTRIES: CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA, 20222029 (USD MILLION) 196
TABLE 260 GCC COUNTRIES: CLINICAL TRIAL IMAGING MARKET, BY END USER,
20222029 (USD MILLION) 196
TABLE 261 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN CLINICAL TRIAL IMAGING MARKET 198
TABLE 262 CLINICAL TRIAL IMAGING MARKET: DEGREE OF COMPETITION 201
TABLE 263 CLINICAL TRIAL IMAGING MARKET: SERVICE & SOFTWARE FOOTPRINT 204
TABLE 264 CLINICAL TRIAL IMAGING MARKET: THERAPEUTIC AREA FOOTPRINT 204
TABLE 265 CLINICAL TRIAL IMAGING MARKET: REGION FOOTPRINT 204
?
TABLE 266 CLINICAL TRIAL IMAGING MARKET: DETAILED LIST OF KEY STARTUPS/SMES 206
TABLE 267 CLINICAL TRIAL IMAGING MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUP/SME PLAYERS 207
TABLE 268 CLINICAL TRIAL IMAGING MARKET: SERVICE AND SOLUTION LAUNCHES AND REGULATORY APPROVALS, JANUARY 2020AUGUST 2024 208
TABLE 269 CLINICAL TRIAL IMAGING MARKET: DEALS, JANUARY 2020AUGUST 2024 209
TABLE 270 ICON PLC: COMPANY OVERVIEW 210
TABLE 271 ICON PLC: SERVICES/SOLUTIONS OFFERED 211
TABLE 272 ICON PLC: SOLUTION LAUNCHES, JANUARY 2020AUGUST 2024 211
TABLE 273 ICON PLC: DEALS, JANUARY 2020AUGUST 2024 212
TABLE 274 MEDPACE: COMPANY OVERVIEW 214
TABLE 275 MEDPACE: SERVICES/SOLUTIONS OFFERED 215
TABLE 276 CLARIO: COMPANY OVERVIEW 216
TABLE 277 CLARIO: SERVICES/SOLUTIONS OFFERED 216
TABLE 278 CLARIO: SOLUTION LAUNCHES, JANUARY 2020AUGUST 2024 217
TABLE 279 CLARIO: DEALS, JANUARY 2020AUGUST 2024 217
TABLE 280 IXICO PLC: COMPANY OVERVIEW 219
TABLE 281 IXICO PLC: SERVICES/SOLUTIONS OFFERED 220
TABLE 282 IXICO PLC: DEALS, JANUARY 2020AUGUST 2024 221
TABLE 283 IXICO PLC: OTHER DEVELOPMENTS, JANUARY 2020AUGUST 2024 221
TABLE 284 RESONANCE HEALTH LTD.: COMPANY OVERVIEW 222
TABLE 285 RESONANCE HEALTH LTD.: SERVICES/SOLUTIONS OFFERED 223
TABLE 286 RESONANCE HEALTH LTD.: SERVICE LAUNCHES AND REGULATORY APPROVALS, JANUARY 2020AUGUST 2024 224
TABLE 287 RESONANCE HEALTH LTD.: DEALS, JANUARY 2020AUGUST 2024 224
TABLE 288 RADIANT SAGE: COMPANY OVERVIEW 225
TABLE 289 RADIANT SAGE: SERVICES/SOLUTIONS OFFERED 225
TABLE 290 WCG CLINICAL: COMPANY OVERVIEW 226
TABLE 291 WCG CLINICAL: SERVICES/SOLUTIONS OFFERED 226
TABLE 292 WCG CLINICAL: DEALS, JANUARY 2021AUGUST 2024 226
TABLE 293 CARDIOVASCULAR IMAGING TECHNOLOGIES: COMPANY OVERVIEW 227
TABLE 294 CARDIOVASCULAR IMAGING TECHNOLOGIES: SERVICES/SOLUTIONS OFFERED 227
TABLE 295 MEDICAL METRICS, INC.: COMPANY OVERVIEW 228
TABLE 296 PRISM CLINICAL IMAGING: COMPANY OVERVIEW 229
TABLE 297 BOSTON IMAGING CORE LAB: COMPANY OVERVIEW 230
TABLE 298 ANAGRAM 4 CLINICAL TRIALS: COMPANY OVERVIEW 231
TABLE 299 VOIANT: COMPANY OVERVIEW 231
TABLE 300 CALYX: COMPANY OVERVIEW 232
TABLE 301 BIOSPECTIVE INC.: COMPANY OVERVIEW 233
TABLE 302 PROSCAN IMAGING: COMPANY OVERVIEW 234
TABLE 303 MICRON, INC.: COMPANY OVERVIEW 235
TABLE 304 IMAGING ENDPOINTS: COMPANY OVERVIEW 236
TABLE 305 PERSPECTUM: COMPANY OVERVIEW 237
?
TABLE 306 PHARMTRACE: COMPANY OVERVIEW 237
TABLE 307 NAVITAS LIFE SCIENCES: COMPANY OVERVIEW 238
TABLE 308 MEDIAN TECHNOLOGIES: COMPANY OVERVIEW 238
TABLE 309 INVICRO, LLC: COMPANY OVERVIEW 239
TABLE 310 IMAGE CORE LAB: COMPANY OVERVIEW 239
TABLE 311 IMAGE ANALYSIS GROUP (IAG): COMPANY OVERVIEW 240
FIGURE 1 CLINICAL TRIAL IMAGING MARKET: SEGMENTS CONSIDERED 31
FIGURE 2 CLINICAL TRIAL IMAGING MARKET: YEARS CONSIDERED 32
FIGURE 3 CLINICAL TRIAL IMAGING MARKET: RESEARCH DESIGN 34
FIGURE 4 CLINICAL TRIAL IMAGING MARKET: KEY DATA FROM SECONDARY SOURCES 35
FIGURE 5 CLINICAL TRIAL IMAGING MARKET: KEY PRIMARY SOURCES
(DEMAND AND SUPPLY SIDES) 36
FIGURE 6 CLINICAL TRIAL IMAGING MARKET: KEY INSIGHTS FROM PRIMARIES 38
FIGURE 7 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 38
FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 39
FIGURE 9 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 40
FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 41
FIGURE 11 CLINICAL TRIAL IMAGING MARKET: TOP-DOWN APPROACH 41
FIGURE 12 DATA TRIANGULATION METHODOLOGY 42
FIGURE 13 CLINICAL TRIAL IMAGING MARKET: STUDY ASSUMPTIONS 43
FIGURE 14 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE,
2024 VS. 2029 (USD MILLION) 45
FIGURE 15 CLINICAL TRIAL IMAGING MARKET, BY MODALITY, 2024 VS. 2029 (USD MILLION) 46
FIGURE 16 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA,
2024 VS. 2029 (USD MILLION) 46
FIGURE 17 CLINICAL TRIAL IMAGING MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 47
FIGURE 18 CLINICAL TRIAL IMAGING MARKET, BY REGION, 2024 VS. 2029 (USD MILLION) 48
FIGURE 19 INCREASE IN R&D SPENDING TO DRIVE MARKET GROWTH 49
FIGURE 20 SERVICES TO DOMINATE CLINICAL TRIAL IMAGING SERVICE & SOFTWARE MARKET IN 2029 49
FIGURE 21 COMPUTED TOMOGRAPHY TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD 50
FIGURE 22 ONCOLOGY TO COMMAND LARGEST MARKET SHARE IN 2029 50
FIGURE 23 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE END-USER MARKET FROM 2024 TO 2029 51
FIGURE 24 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING STUDY PERIOD 51
FIGURE 25 CLINICAL TRIAL IMAGING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 52
FIGURE 26 NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (20002022) 53
FIGURE 27 PATENT APPLICATIONS FOR CLINICAL TRIAL IMAGING
(JANUARY 2013DECEMBER 2023) 57
FIGURE 28 CLINICAL TRIAL IMAGING MARKET: VALUE CHAIN ANALYSIS 60
FIGURE 29 CLINICAL TRIAL IMAGING MARKET: SUPPLY CHAIN ANALYSIS 61
FIGURE 30 CLINICAL TRIAL IMAGING MARKET: ECOSYSTEM ANALYSIS 62
FIGURE 31 CLINICAL TRIAL IMAGING MARKET: PORTERS FIVE FORCES ANALYSIS 63
FIGURE 32 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF CLINICAL TRIAL IMAGING SERVICES/SOLUTIONS 65
FIGURE 33 KEY BUYING CRITERIA FOR MAJOR END USERS 66
FIGURE 34 CLINICAL TRIAL IMAGING MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 73
FIGURE 35 R&D INVESTMENTS IN PHARMACEUTICAL INDUSTRY, 20122026 (USD BILLION) 126
FIGURE 36 NORTH AMERICA: CLINICAL TRIAL IMAGING MARKET SNAPSHOT 141
FIGURE 37 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET SNAPSHOT 167
FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS IN CLINICAL TRIAL IMAGING MARKET (20212023) 200
FIGURE 39 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CLINICAL TRIAL IMAGING MARKET (2023) 200
FIGURE 40 CLINICAL TRIAL IMAGING MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 203
FIGURE 41 CLINICAL TRIAL IMAGING MARKET: COMPANY FOOTPRINT 203
FIGURE 42 CLINICAL TRIAL IMAGING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 206
FIGURE 43 EV/EBITDA OF KEY VENDORS 207
FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
KEY VENDORS 208
FIGURE 45 ICON PLC: COMPANY SNAPSHOT 211
FIGURE 46 MEDPACE: COMPANY SNAPSHOT 214
FIGURE 47 IXICO PLC: COMPANY SNAPSHOT 219
FIGURE 48 RESONANCE HEALTH LTD.: COMPANY SNAPSHOT 223
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security